Skip to menu Skip to search Skip to content Skip to footer

Advanced BioDesign

  • Pharmaceutical industry and medical biology / biotech
  • Biotech research
  • Drugs and vaccines development
  • Cancer / oncology

Presentation

Developing a targeted therapy aimed at restoring cell death mechanisms in cancer cells in order to overcome tumor chemoresistance.

Advanced BioDesign (ABD) is a biotechnology company founded in 2010 that aims to restore cell death mechanisms in cancer cells to overcome tumor chemoresistance by targeting cancer cell metabolism and more specifically aldehyde dehydrogenase class 1 (ALDH1) . Its lead anti-cancer compound, DIMATE (ABD-3001), is a first-in-class suicide inhibitor of aldehydes dehydrogenases 1&3 (ALDH1&3). Advanced BioDesign has completed the preclinical stages of ABD-3001 and obtained authorisation in January 2022 from the French National Agency for Drug Safety (ANSM – Agence Nationale de Sécurité du Médicament) for its first human trial which started in November 2022. Based in Lyon, Advanced BioDesign is supported and accompanied by Xerys funds which have been financing its research and development programs since 2013.

Products

Targeted therapy, ODYSSEY

  • ABD-3001

    ABD-3001 is the pharmacological form of DIMATE that targets and inhibits a detoxification system present within cancer cells. This detoxification is strongly active in most tumor or leukemic cells, enabling them to survive the inevitable metabolic disorders that occur during the cancer process. By inhibiting this cellular protection system, DIMATE poisons and kills off cancer cells, without harming healthy cells.

    The first-in-human phase I clinical trial in acute myeloid leukemia (AML) is a multi-center study (Paris, Lyon, Marseille) intended to evaluate the safety and tolerance of the ABD-3001.